Open Access

Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection

  • Emmalene J. Bartlett1,
  • Vanessa S. Cull1,
  • Eva N. Mowe1,
  • Josephine P. Mansfield1 and
  • Cassandra M. James1Email author
Biological Procedures Online5:51043

Received: 10 December 2002

Accepted: 5 February 2003


Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of post-viral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200µgIFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMVgB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.

Indexing terms

interferonsgene therapycytomegalovirusDNA